Navigation Links
MMJ Files FDA Fast Track Approval Application For Cannabis Multiple Sclerosis Drug
Date:2/13/2019

MMJ International Holdings, the premier medical cannabis research company, is advancing the science of medical marijuana legally through patient clinical trials and research, announced that it is seeking fast track designation approval from the FDA.

The FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill patients unmet medical needs. MMJ-001 the companies new cannabis based pharmaceutical drug for multiple sclerosis will show robust treatment results.

The MMJ Group is focused on collaborative scientific research projects that follows the FDA guidelines. MMJ will conduct its clinical trials to fully explore the potential of cannabis medicine for progressive Multiple Sclerosis and Huntington's patients.

Bianca Weinstock-Guttman MD, MMJ International Holding's principal investigator is a widely known leading expert on multiple sclerosis (MS) in adults and children. She also is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

MMJ International Holdings will begin a first "dose ranging" study comparing its pharmaceutical formulation of THC and CBD to placebo. It is expected that the study will demonstrate acceptable tolerable patient doses of the medicine.

Duane Boise the company’s CEO stated, "The positive data from this dosing study is important in that it will provide us with the necessary evidence on patient tolerance to different doses of THC and CBD for the treatment for PPMS. This information will prove value to assist clinicians with prescribing decisions to address individual patient needs should this medicine be FDA approved for use."

MMJ International Holdings team continues to evaluate numerous plant derived cannabinoid medicines and currently has several planned clinical trials including Huntington’s disease. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis. For further information, please visit http://www.mmjih.com

Read the full story at https://www.prweb.com/releases/mmj_files_fda_fast_track_approval_application_for_cannabis_multiple_sclerosis_drug/prweb16100751.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. NXT-ID Inc. Files 2016 Annual Report on Form 10-K
2. Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token
3. Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market
4. LaserLock Technologies Files A New Provisional Patent Which Secures Player Identity On Internet Gaming Platforms
5. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
6. Utah Department of Health to Track Newborn Screening Specimens Statewide with Track-Kit™ from STACS DNA
7. Global Eye Tracking Market - Analysis, Technologies & Forecasts to 2021 - Increasing Demand for Contactless Biometrics - Research and Markets
8. Cloudtag Announces Onitor Track, a Weight Loss Program and Wearable for the Age of Data, at the 2017 Consumer Electronics Show
9. Avanade Tracks Williams Martini Racing Pit Crew Biometrics To Boost Future F1 Performance
10. MWC: Mobile Virtual Reality Boosted by SMIs Proven Eye Tracking and Foveated Rendering Technology
11. Rite Track Acquires Plus LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2019)... ... 17, 2019 , ... USDM Life Sciences (USDM) announces that Jay Crowley, Vice ... for Creating a Sustainable Global UDI Compliance Strategy at the European UDI Forum on ... , What device manufacturers did to comply with the US FDA UDI rule ...
(Date:4/16/2019)... ... April 16, 2019 , ... ... and search firms with over $2 billion in placement fees to recruiters and ... and employee onboarding platform, ExactHire. , This strategic relationship with ExactHire is ...
(Date:4/16/2019)... Md. (PRWEB) , ... April 16, 2019 , ... ... announced its featured speakers for two signature events: The 2019 ISPE Biopharmaceutical ... Workshop on 20–21 June. Taking place in one of the most influential ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... April 10, 2019 , ... ... have locked into multiple agreements to help companies advance their innovations to ... industry, ranging from synthetic biology companies that are gene editing therapeutic cells ...
(Date:4/9/2019)... ... ... The American Society of Gene & Cell Therapy (ASGCT) is excited to ... the presidential line of succession, at the 22nd Annual Meeting . Members of ... three-year term (2019-2021). , All five incoming members of the ASGCT Board of ...
(Date:4/4/2019)... ... , ... Biomeme, Inc. , a leading manufacturer of ... for performing PCR, RT-PCR, qPCR, and Isothermal tests called Franklin ™. The ... English chemist and X-ray crystallographer who made significant contributions to the understanding of ...
(Date:3/27/2019)... ... March 27, 2019 , ... In honor of National Nutrition Month, ... importance of healthy meals and good nutrition. This month, Chef Jodi Abel appeared ... chef. , The first segment addressed the nutritional value of USDA’s MyPlate, ...
Breaking Biology Technology: